GlassScriptPhysician profile
Vitaliy Shaulov
NPI 1699705590
$12,417.62
in general payments reported to CMS, 2019-2025
41 companies · $670 in 2025
The $670 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $1,239 · 2021: $2,667 · 2022: $2,200 · 2023: $2,714 · 2024: $1,259 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,637 · Education: $6.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,636.98 |
| Education | $6.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,514.25 | 2019-2025 | Rexulti, Abilify Mycite |
| Vanda Pharmaceuticals INC. | $1,348.63 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $1,203.67 | 2021-2025 | Vraylar, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $864.72 | 2019-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $817.15 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $757.10 | 2021-2025 | Caplyta |
| Lundbeck LLC | $713.86 | 2019-2025 | Rexulti, Brintellix |
| Bausch Health US, LLC | $527.16 | 2019-2024 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $454.01 | 2019-2024 | Jornay Pm |
| Alkermes, INC. | $453.46 | 2021-2025 | Aristada, Lybalvi |
| Allergan, INC. | $433.93 | 2019-2020 | |
| Adlon Therapeutics L.P. | $347.81 | 2020-2021 | |
| Corium, LLC | $324.07 | 2021-2024 | Azstarys |
| Tris Pharma INC | $273.69 | 2019-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $243.12 | 2019-2023 | Belsomra |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $207.93 | 2022-2025 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $176.30 | 2022-2024 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $173.88 | 2019-2025 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $168.14 | 2019-2022 | |
| Almatica Pharma LLC | $155.39 | 2021-2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $150.08 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $126.00 | 2019-2025 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $125.62 | 2019-2020 | |
| Alfasigma USA, INC. | $109.48 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $94.25 | 2022-2024 | Quviviq |
| Eisai INC. | $91.04 | 2020-2022 | |
| Noven Therapeutics, LLC | $90.61 | 2021-2024 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $82.31 | 2024-2025 | Cobenfy |
| Owp Pharmaceuticals, INC. | $77.09 | 2020-2022 | |
| Livanova USA, INC. | $70.65 | 2021-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Acadia Pharmaceuticals INC | $42.65 | 2019 | |
| Braeburn INC. | $23.47 | 2023 | Brixadi |
| Indivior INC. | $22.63 | 2021 | |
| Vertical Pharmaceuticals, LLC | $20.51 | 2020 | |
| Avanir Pharmaceuticals, INC. | $20.17 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.99 | 2020 | |
| Azurity Pharmaceuticals, INC. | $19.98 | 2025 | Horizant |
| Collegium Pharmaceutical, INC. | $19.92 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $19.76 | 2020 | |
| Aytu Biopharma, INC. | $17.57 | 2021 | |
| Assertio Therapeutics, INC. | $15.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vitaliy Shaulov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.